This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Opexa Announces Issuance Of 50th Patent For T-cell Immunotherapy Platform

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that several key patents have issued, further strengthening the Company's proprietary technology for the development of patient-specific immunotherapies.

Opexa licenses and maintains a variety of patents covering the treatment of autoimmune diseases, including MS. In the past year alone, Opexa has received eight patents or notices of allowance for related inventions, including a key patent recently issued by the European patent office. The European patent is the fiftieth (50 th) patent awarded worldwide under Opexa's direction for its proprietary T-cell platform and validates Opexa as a leader in the field of Precision Immunotherapy TM. Opexa has a broad patent portfolio protecting its technology in the United States, Europe and Asia.

European patent no. 2335720 was recently granted and is valid in 18 European countries. The European patent covers the manufacture of patient-specific T-cell vaccines created using immunogenic fragments of myelin proteins. It further protects the use of Tcelna as a treatment for MS. Tcelna, Opexa's leading pharmaceutical candidate, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program for the treatment of Secondary Progressive MS (SPMS). Tcelna has been granted Fast Track Designation from the United States Food and Drug Administration (FDA) for the treatment of SPMS.

Additional patents that have recently been granted include European patent no. 1677821, which is directed toward a T-cell vaccine enriched in CD8 + T-cells for treating MS, and Israeli patent no. 195115, granted for personalized T-cell vaccines comprising T-cells specific to the most immunogenic epitopes of any autoantigen. A notice of allowance was received last month with respect to U.S. patent application no. 12/306,894, directed toward the use of a personalized T-cell vaccine for the treatment of rheumatoid arthritis.

"As a leader in the novel field of Precision Immunotherapy, it is vital that we build and protect our intellectual property position globally. This serves to maintain our competitive advantage and also enables us to build incremental shareholder value," stated Neil K. Warma, President and CEO of Opexa. "It is critical that we not only maintain and defend the strong patent estate we have built for Tcelna in MS, but we believe it is also important to our long-term growth to seek patent coverage for the potential use of our proprietary technology to treat other autoimmune diseases.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs